Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of Latanoprost and Dorzolamide in healthy males
NCT05207761Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of latanoprost and dorzolamide in Glaucoma (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve at steady state over the dosing interval and Maximum Plasma Concentration at steady state. Started Jan 2022; status: completed.
02
Drugs
latanoprostdorzolamide
03
Conditions
Glaucoma
Beyond the preview
Go deeper on NCT05207761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207761.